Evotec SE: Evotec and Crohn s & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD Therapies finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
EQS-News: Evotec SE / Key word: Miscellaneous
Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies
10.01.2024 /.
Evotec SE (NASDAQ: EVO) joined forces with the Crohn's & Colitis Foundation to advance drug discovery and identify novel therapies for inflammatory bowel disease (IBD).
Evotec’s end-to-end integrated research and development platform will be able to advance drug discovery for two drug targets which is why it has joined forces with the Crohn’s & Colitis Foundation.